Amerisourcebergen reports q1 adj eps of $1.76

Amerisourcebergen reports fiscal 2020 first quarter results.sees fy 2020 adjusted earnings per share $7.55 to $7.80.q1 adjusted earnings per share $1.76.q1 gaap earnings per share $0.90.q1 earnings per share estimate $1.67 -- refinitiv ibes data.qtrly revenues of $47.9 billion for q1, a 5.4 percent increase year-over-year.board of directors increased quarterly dividend rate by 5% to $0.42 per share.fy2020 earnings per share view $7.53 -- refinitiv ibes data.q1 revenue, adjusted. profit growth driven by pharmaceutical distribution and global commercialization services & animal health groups.in late january 2020 company decided to exit pharmedium compounding business.amerisourcebergen - increased fiscal 2020 guidance reflects ongoing strength of business, removal of pharmedium's operating. loss for remainder of year.pharmedium impairment charge of $138 million recognized in three months ended december 31, 2019.amerisourcebergen - in q2, sees to impair remaining $55 million of pharmedium tangible assets, all of remaining $185 million of pharmedium intangible assets.amerisourcebergen - sees fy other costs in connection with exiting pharmedium compounding to total about $80 million to $100 million.amerisourcebergen-due to pharmedium compounding business exit, estimate will realize cash tax benefit about $500- $600 million in fiscal 2020 through 2022.
ABC Ratings Summary
ABC Quant Ranking